Cliff Caldwell Appointed CEO of CIL
Cambridge Isotope Laboratories, Inc. (CIL) board of directors appointed Cliff Caldwell as its new chief executive officer (CEO), as Joel Bradley, founder and CEO, stepped down from his position after 38 years.
TEWKSBURY, Mass., October 29, 2019 (Newswire.com) - Caldwell has more than 30 years’ international executive management experience in the manufacture of industrial gases, specialty gases, and chemicals, serving the electronics, pharmaceutical, chemical, research, and high-technology industries. Most recently, he served as a senior vice president with The Linde Group, where he had proven success generating sales, driving organic growth, and increasing revenue in highly dynamic markets.
“Cliff is very familiar with CIL. He has been a customer and already knows many parts of the stable isotope business,” says Bradley. “In his work at Linde, Cliff supervised operations, including production of isotopes and many other UHP gases and specialty electronic products.”
“I’m excited to be leading CIL in its next phases of development,” adds Caldwell. “CIL has the most experienced professionals, exceptionally reliable production, and a strong reputation supporting our customers around the world.”
About Cambridge Isotope Laboratories, Inc.
CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL Canada in Montreal, Canada; CIL China in Shanghai; ABX in Dresden, Germany; and Eurisotop in Saclay, France.
For more information on CIL, visit isotope.com.
Source: Cambridge Isotope Laboratories, Inc.